ELEVIDYS dominates Sarepta's revenue base; non-ambulant label restoration and PMO traditional approval conversions are the conditions that determine the next leg of value

Bull

A favorable FDA response to the immunosuppression protocol submission, followed by clean safety and efficacy data from the ~25 non-ambulatory participants in ENDEAVOR Cohort 8 using prophylactic sirolimus, would support resubmission and restoration of the non-ambulant label. This would meaningfully expand the treatable population beyond the current ambulatory-only indication, reigniting ELEVIDYS revenue growth and validating the gene therapy's utility across the full DMD disease spectrum.

Bear

The most likely failure modes are persistent serious liver injury signals in non-ambulant patients despite the enhanced sirolimus-based immunosuppression regimen, or FDA requiring a larger or longer dataset before reconsidering the label — both of which would delay or permanently foreclose non-ambulant label restoration. Non-ambulant patients tend to have more advanced disease and greater immune activation risk, raising the bar for a clean safety profile, and any new hepatotoxicity event in Cohort 8 could further entrench the boxed warning and reduce prescriber confidence across all ELEVIDYS-treated patients.